Aroa Biosurgery Limited (ASX: ARX), a soft tissue regeneration company, announced positive results from a prospective, multicenter randomized controlled tr...
AAVantgarde Bio (AAVantgarde), the clinical-stage biotechnology company developing genetic medicines for inherited retinal diseases (IRDs) using its propri...
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, announced three-year follow-up results from the ovarian cancer cohort of its 400+ patie...
All 24 patients completed treatment with no dose-limiting toxicities, no Grade 3 or higher adverse events related to JNJ-1900 (NBTXR3 or to the injecti...
Detailed Phase 3 CANOPY-HCH-3 data in children living with hypochondroplasia also featured in a late-breaking oral presentation at th...
HUTCHMED (China) Limited announces that positive high-level results from the SAFFRON Phase III trial showed ORPATHYS® (savolitinib) plus TAGRISSO®...
Phase 3 VISIONARY study met its key secondary endpoint, showing an annualized estimated eGFR slope of +0.3 (95% CI, -0.4 to 0.9) mL/min/1.73 m²/...
SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a ...
Dasher Neuroscience Holdings Inc. (TPEx: 7829) ("Dasher Neuroscience"), an AI-driven biopharmaceutical company focused on central nervous system (CNS) dr...
Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and pote...
ASC48 is a potentially first-in-class oral small molecule GIPR agonist. - ASC48 demonstrated an EC50 of 1 pM in the hGIPR cAMP activation assay, exhibit...
BGE-102, a potent, structurally novel, orally available, brain-penetrant small molecule NLRP3 inhibitor developed from a hit identi...
AI hasn’t taken over clinical trials. It’s taken over the parts of clinical trials nobody wanted to do manually in the first place. Clinicians ...
Since people rely on this type of care for practically everything, be it preventing an illness or managing one, a strong workforce is needed. Now, t...
© 2026 Biopharma Boardroom. All Rights Reserved.
